pharma · Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis (PFIC) · MIRM
Mirum Pharmaceuticals International
Mirum Pharmaceuticals International B.V.
Mirum Pharmaceuticals International clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US
- Founded
- 2018
- Employees
- 436
- Programs
- 25
- Drugs
- 10
- Patents
- 4
Mirum Pharmaceuticals International projects
8 ClinicalTrials.gov programs sponsored by Mirum Pharmaceuticals International.
Mirum Pharmaceuticals International has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Blinded CDCA 250 mg TID
Mirum Pharmaceuticals International B.V.
CTX
1 trial -
Brelovitug (BJT-778)
Mirum Pharmaceuticals International B.V.
Chronic Hepatitis D
1 trial -
Brelovitug 300 mg
Mirum Pharmaceuticals International B.V.
Chronic Hepatitis D Infection
3 trials -
Cholic Acid
Mirum Pharmaceuticals International B.V.
Bile Acid Synthesis Defect
1 trial -
Cholic Acids
Mirum Pharmaceuticals International B.V.
Infantile Refsum's Disease
1 trial -
Cholic acid
Mirum Pharmaceuticals International B.V.
Inborn Errors of Bile Acid Synthesis
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis (PFIC)
3 trials
Frequently asked questions
How many clinical projects does Mirum Pharmaceuticals International have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.